Resumen

GONZALEZ ANDUJO, Adriana et al. Prophylactic effect of pravastatin in the incidence of ventilator-associated pneumonia (VAP). Rev. Asoc. Mex. Med. Crít. Ter. Intensiva [online]. 2015, vol.29, n.4, pp.214-221. ISSN 0187-8433.

Objective: To determine whether prophylactic pravastatin compared to placebo reduces the risk of ventilator-associated pneumonia (VAP). Material and methods: A double-blind controlled clinical trial, was conducted at the Internal Medicine Service, Xoco General Hospital, Mexico City in 44 intubated patients who met the inclusion criteria and were randomly assigned to receive pravastatin 40 mg (or 10 mg in case of kidney failure) (n = 22) or placebo (n = 22). Groups were followed for 10 days or until the patient's death. Results: Fourteen (32.55%) of the 44 patients developed VAP, eight (36.3%) in the pravastatin group and 6 (28.7%) in the placebo group (p = 0.51). Overall mortality was 39% (17/44), and by treatment group, ocurred in 36.3% (8/22) patients in the pravastatin group and 42.8% (9/22) in the placebo group (p = 0.53). Conclusions: No benefit of prophylactic administration of pravastatin in the incidence of VAP was observed. We consider necessary to investigate a possible beneficial effect of statins on survival of patients with established infection.

Palabras llave : Incidence; ventilator-associated pneumonia; mortality; pravastatin.

        · resumen en Español     · texto en Español     · Español ( pdf )